2 minute read
Jan. 28, 2023

DN-1289: What Happened to DLK as a Target?


selective, CNS-penetrant dual DLK/LZK inhibitor neuroprotective effects for in vivo + in vitro models for ALS LBDD/SBDD + opt. J. Med. Chem., December 5, 2022 Denali Therapeutics, South San Fransisco, CA

Drug Hunter Team

DN-1289 is a CNS-penetrant, ATP-competitive DLK/LZK-selective dual kinase inhibitor intended to treat amyotrophic lateral sclerosis (ALS). The molecule is structurally closely related to Genentech’s recent Ph. I candidate, GDC-0134. Why does everyone seem to have stopped working on DLK? [...]



Other molecules you may be interested in